

FOR IMMEDIATE RELEASE

PRA Health Sciences Expands Global Phase I Patient Strategy

30 March 2014, Raleigh, North Carolina

PRA Health Sciences (PRA) is enhancing its global Phase I patient strategy and increasing its clinical footprint with the expansion of its Early Development Services (EDS). These initiatives are being undertaken in response to market demand to include patients as early as possible in early phase clinical trial development and include:

- Opening an 11,000 square foot outpatient facility at PRA's Salt Lake City, Utah site, focusing on psychiatry, neurology, pain and multiple other therapeutic areas. The new facility includes a dedicated pharmacy, clinical lab and surgical suites.
- Further enhancing PRA's U.S. patient capabilities and service offerings by implementing proven operational site models in our Marlton, New Jersey facility similar to those utilized in our Patient Pharmacology Services operations in Central and Eastern Europe.
- Expanding PRA's Patient Pharmacology Services into Russia. The first clinical trial application was recently submitted for a rheumatoid arthritis patient study and approval is expected in April.
- Expanding PRA's Human Abuse Liability (HAL) study capabilities at its Lenexa, Kansas site. This positions PRA as the only contract research organization (CRO) capable of conducting these specialized trials in more than one clinical pharmacology unit.

"With PRA conducting more than half of its Phase I/IIa studies in patients vs. volunteers, these initiatives will further enhance our U.S. patient capabilities and service offerings," said Randall Hein, Senior Vice President, Clinical Research Services.

Arnoud Huisman, MSc, Senior Vice President Global Business Development, EDS added, "This increased capacity will allow PRA to meet the increased high demand for patient studies, HAL studies, pain and other indications."

PRA EDS is a business unit of PRA Health Sciences, offering full service Phase I capabilities and Phase I-III patient site services. Global capabilities include: eight clinical pharmacology units, two bioanalytical laboratories, as well as dedicated clinical pharmacology, statistics, data management and pharmacokinetics services.

MEDIA INQUIRIES: Christine Rogers, Manager – Public Relations, Corporate Communications
EMAIL: rogerschristine@praahs.com **PHONE:** +1 919.786.8463
INVESTOR INQUIRIES: InvestorRelations@praahs.com

FOR IMMEDIATE RELEASE

ABOUT PRA HEALTH SCIENCES

PRA Health Sciences is one of the world's leading global contract research organizations (CRO), providing outsourced clinical development services to the biotechnology and pharmaceutical industries. At PRA, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.

MEDIA INQUIRIES: Christine Rogers, Manager – Public Relations, Corporate Communications
EMAIL: rogerschristine@praht.com **PHONE:** +1 919.786.8463
INVESTOR INQUIRIES: InvestorRelations@praht.com